journal
https://read.qxmd.com/read/33845037/surveillance-for-subsequent-neoplasms-of-the-cns-for-childhood-adolescent-and-young-adult-cancer-survivors-a-systematic-review-and-recommendations-from-the-international-late-effects-of-childhood-cancer-guideline-harmonization-group
#1
REVIEW
Daniel C Bowers, Lisanne C Verbruggen, Leontien C M Kremer, Melissa M Hudson, Roderick Skinner, Louis S Constine, Noah D Sabin, Ranjeev Bhangoo, Riccardo Haupt, Mike M Hawkins, Helen Jenkinson, Raja B Khan, Paul Klimo, Pieter Pretorius, Antony Ng, Raoul C Reulen, Cécile M Ronckers, Zsila Sadighi, Katrin Scheinemann, Netteke Schouten-van Meeteren, Elaine Sugden, Jop C Teepen, Nicole J Ullrich, Andrew Walter, W Hamish Wallace, Kevin C Oeffinger, Gregory T Armstrong, Helena J H van der Pal, Renée L Mulder
Exposure to cranial radiotherapy is associated with an increased risk of subsequent CNS neoplasms among childhood, adolescent, and young adult (CAYA) cancer survivors. Surveillance for subsequent neoplasms can translate into early diagnoses and interventions that could improve cancer survivors' health and quality of life. The practice guideline presented here by the International Late Effects of Childhood Cancer Guideline Harmonization Group was developed with an evidence-based method that entailed the gathering and appraisal of published evidence associated with subsequent CNS neoplasms among CAYA cancer survivors...
April 9, 2021: Lancet Oncology
https://read.qxmd.com/read/33845036/increasing-the-value-of-radiotherapy-in-breast-cancer
#2
Thomas A Buchholz
No abstract text is available yet for this article.
April 9, 2021: Lancet Oncology
https://read.qxmd.com/read/33845035/intraoperative-irradiation-for-early-breast-cancer-eliot-long-term-recurrence-and-survival-outcomes-from-a-single-centre-randomised-phase-3-equivalence-trial
#3
Roberto Orecchia, Umberto Veronesi, Patrick Maisonneuve, Viviana Enrica Galimberti, Roberta Lazzari, Paolo Veronesi, Barbara Alicja Jereczek-Fossa, Federica Cattani, Claudia Sangalli, Alberto Luini, Pietro Caldarella, Marco Venturino, Daniele Sances, Stefano Zurrida, Giuseppe Viale, Maria Cristina Leonardi, Mattia Intra
BACKGROUND: In the randomised, phase 3 equivalence trial on electron intraoperative radiotherapy (ELIOT), accelerated partial breast irradiation (APBI) with the use of intraoperative radiotherapy was associated with a higher rate of ipsilateral breast tumour recurrence (IBTR) than whole-breast irradiation (WBI) in patients with early-stage breast cancer. Here, we aimed to examine the planned long-term recurrence and survival outcomes from the ELIOT trial. METHODS: This single-centre, randomised, phase 3 equivalence trial was done at the European Institute of Oncology (Milan, Italy)...
April 9, 2021: Lancet Oncology
https://read.qxmd.com/read/33845034/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or-metastatic-cervical-cancer-innovatv-204-gog-3023-engot-cx6-a-multicentre-open-label-single-arm-phase-2-study
#4
Robert L Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martín, Leslie Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frederic Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R Harris, Margaret Smith, Leonardo Viana Nicacio, Melinda S L Teng, Annouschka Laenen, Reshma Rangwala, Luis Manso, Mansoor Mirza, Bradley J Monk, Ignace Vergote
BACKGROUND: Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody-drug conjugate, in this patient population. METHODS: This multicentre, open-label, single-arm, phase 2 study was done across 35 academic centres, hospitals, and community practices in Europe and the USA. The study included patients aged 18 years or older who had recurrent or metastatic squamous cell, adenocarcinoma, or adenosquamous cervical cancer; disease progression on or after doublet chemotherapy with bevacizumab (if eligible by local standards); who had received two or fewer previous systemic regimens for recurrent or metastatic disease; had measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST; version 1...
April 9, 2021: Lancet Oncology
https://read.qxmd.com/read/33838740/new-technical-guidance-to-boost-global-radiotherapy-access
#5
Emma Wilkinson
No abstract text is available yet for this article.
April 8, 2021: Lancet Oncology
https://read.qxmd.com/read/33812497/health-related-quality-of-life-in-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal-cancer-treated-with-first-line-pembrolizumab-versus-chemotherapy-keynote-177-an-open-label-randomised-phase-3-trial
#6
Thierry Andre, Mayur Amonkar, Josephine M Norquist, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J A Punt, Denis Smith, Rocio Garcia-Carbonero, Isabel Sevilla, Christelle De La Fouchardiere, Fernando Rivera, Elena Elez, Luis A Diaz, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Farooqui, Dung T Le
BACKGROUND: In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically significant and clinically meaningful improvements in progression-free survival versus chemotherapy as first-line treatment in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. To further support the efficacy and safety findings of the KEYNOTE-177 study, results of the health-related quality of life (HRQOL) analyses are reported here. METHODS: KEYNOTE-177 is an open-label, randomised, phase 3 trial being done at 192 cancer centres in 23 countries, in patients aged 18 years and older with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and who had not received previous systemic therapy for metastatic disease...
April 1, 2021: Lancet Oncology
https://read.qxmd.com/read/33812496/new-canadian-law-on-medical-assisted-dying
#7
Manjulika Das
No abstract text is available yet for this article.
April 1, 2021: Lancet Oncology
https://read.qxmd.com/read/33812495/short-term-safety-of-the-bnt162b2-mrna-covid-19-vaccine-in-patients-with-cancer-treated-with-immune-checkpoint-inhibitors
#8
Barliz Waissengrin, Abed Agbarya, Esraa Safadi, Hagit Padova, Ido Wolf
No abstract text is available yet for this article.
April 1, 2021: Lancet Oncology
https://read.qxmd.com/read/33811814/8th-european-conference-on-infections-in-leukaemia-2020-guidelines-for-the-use-of-antibiotics-in-paediatric-patients-with-cancer-or-post-haematopoietic-cell-transplantation
#9
REVIEW
Thomas Lehrnbecher, Dina Averbuch, Elio Castagnola, Simone Cesaro, Roland A Ammann, Carolina Garcia-Vidal, Jukka Kanerva, Fanny Lanternier, Alessio Mesini, Malgorzata Mikulska, Dorothea Pana, Nicole Ritz, Monica Slavin, Jan Styczynski, Adilia Warris, Andreas H Groll
Paediatric patients with cancer and those undergoing haematopoietic cell transplantation are at high risk of bacterial infections. The 8th European Conference on Infections in Leukaemia (ECIL-8) convened a Paediatric Group to review the literature and to formulate recommendations for the use of antibiotics according to the European Society of Clinical Microbiology and Infectious Diseases grading system. The evaluation of antibacterial prophylaxis included mortality, bloodstream infection, febrile neutropenia, emergence of resistance, and adverse effects as endpoints...
March 31, 2021: Lancet Oncology
https://read.qxmd.com/read/33811813/8th-european-conference-on-infections-in-leukaemia-2020-guidelines-for-the-diagnosis-prevention-and-treatment-of-invasive-fungal-diseases-in-paediatric-patients-with-cancer-or-post-haematopoietic-cell-transplantation
#10
REVIEW
Andreas H Groll, Dorothea Pana, Fanny Lanternier, Alessio Mesini, Roland A Ammann, Dina Averbuch, Elio Castagnola, Simone Cesaro, Dan Engelhard, Carolina Garcia-Vidal, Jukka Kanerva, Nicole Ritz, Emmanuel Roilides, Jan Styczynski, Adilia Warris, Thomas Lehrnbecher
Paediatric patients with cancer and those undergoing allogeneic haematopoietic cell transplantation have an increased susceptibility to invasive fungal diseases. In addition to differences in underlying conditions and comorbidities relative to adults, invasive fungal diseases in infants, children, and adolescents are unique in terms of their epidemiology, the validity of current diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of phase 3 clinical trials to provide data to guide evidence-based interventions...
March 31, 2021: Lancet Oncology
https://read.qxmd.com/read/33798493/second-line-folfox-chemotherapy-versus-active-symptom-control-for-advanced-biliary-tract-cancer-abc-06-a-phase-3-open-label-randomised-controlled-trial
#11
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, Paul J Ross, Yuk Ting Ma, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Tim Iveson, Justin S Waters, Claire Hobbs, Safia Barber, W David Ryder, John Ramage, Linda M Davies, John A Bridgewater, Juan W Valle
BACKGROUND: Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of this study was to determine the benefit derived from second-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy in advanced biliary tract cancer. METHODS: The ABC-06 clinical trial was a phase 3, open-label, randomised trial done in 20 sites with expertise in managing biliary tract cancer across the UK...
March 30, 2021: Lancet Oncology
https://read.qxmd.com/read/33773616/extent-of-french-nuclear-tests-in-polynesia-revealed
#12
Manjulika Das
No abstract text is available yet for this article.
March 25, 2021: Lancet Oncology
https://read.qxmd.com/read/33773615/china-s-oncology-drug-market-on-the-rise
#13
Chris McCall
No abstract text is available yet for this article.
March 25, 2021: Lancet Oncology
https://read.qxmd.com/read/33773614/carcinogenicity-of-gentian-violet-leucogentian-violet-malachite-green-leucomalachite-green-and-ci-direct-blue-218
#14
(no author information available yet)
No abstract text is available yet for this article.
March 25, 2021: Lancet Oncology
https://read.qxmd.com/read/33765422/real-time-fluorescence-imaging-in-intraoperative-decision-making-for-cancer-surgery
#15
REVIEW
Lorraine J Lauwerends, Pieter B A A van Driel, Robert J Baatenburg de Jong, José A U Hardillo, Senada Koljenovic, Gerwin Puppels, Laura Mezzanotte, Clemens W G M Löwik, Eben L Rosenthal, Alexander L Vahrmeijer, Stijn Keereweer
Fluorescence-guided surgery is an intraoperative optical imaging method that provides surgeons with real-time guidance for the delineation of tumours. Currently, in phase 1 and 2 clinical trials, evaluation of fluorescence-guided surgery is primarily focused on its diagnostic performance, although the corresponding outcome variables do not inform about the added clinical benefit of fluorescence-guided surgery and are challenging to assess objectively. Nonetheless, the effect of fluorescence-guided surgery on intraoperative decision making is the most objective outcome measurement to assess the clinical value of this imaging method...
March 22, 2021: Lancet Oncology
https://read.qxmd.com/read/33751930/oda-budget-cuts-will-affect-global-cancer-research
#16
Talha Khan Burki
No abstract text is available yet for this article.
March 19, 2021: Lancet Oncology
https://read.qxmd.com/read/33743851/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive-relapsed-ovarian-cancer-and-a-brca1-2-mutation-solo2-engot-ov21-a-final-analysis-of-a-double-blind-randomised-placebo-controlled-phase-3-trial
#17
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine
BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial. The aim of this final analysis is to investigate the effect of olaparib on overall survival. METHODS: This double-blind, randomised, placebo-controlled, phase 3 trial was done across 123 medical centres in 16 countries...
March 18, 2021: Lancet Oncology
https://read.qxmd.com/read/33721562/pembrolizumab-versus-brentuximab-vedotin-in-relapsed-or-refractory-classical-hodgkin-lymphoma-keynote-204-an-interim-analysis-of-a-multicentre-randomised-open-label-phase-3-study
#18
John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Goncalves, Jose S R de Oliveira, Valeria Buccheri, Guilherme F Perini, Neta Goldschmidt, Iryna Kriachok, Michael Dickinson, Mieczyslaw Komarnicki, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Ying Zhu, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani
BACKGROUND: PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma. METHODS: In this randomised, open-label, phase 3 study, patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma with measurable disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 who were ineligible for or had relapsed after autologous haematopoietic stem-cell transplantation (HSCT) were enrolled at 78 hospitals and cancer centres in 20 countries and territories...
March 12, 2021: Lancet Oncology
https://read.qxmd.com/read/33721561/70-gene-signature-as-an-aid-for-treatment-decisions-in-early-breast-cancer-updated-results-of-the-phase-3-randomised-mindact-trial-with-an-exploratory-analysis-by-age
#19
Martine Piccart, Laura J van 't Veer, Coralie Poncet, Josephine M N Lopes Cardozo, Suzette Delaloge, Jean-Yves Pierga, Peter Vuylsteke, Etienne Brain, Suzan Vrijaldenhoven, Peter A Neijenhuis, Sylvian Causeret, Tineke J Smilde, Giuseppe Viale, Annuska M Glas, Mauro Delorenzi, Christos Sotiriou, Isabel T Rubio, Sherko Kümmel, Gabriele Zoppoli, Alastair M Thompson, Erika Matos, Khalil Zaman, Florentine Hilbers, Debora Fumagalli, Peter Ravdin, Susan Knox, Konstantinos Tryfonidis, Aleksandra Peric, Bart Meulemans, Jan Bogaerts, Fatima Cardoso, Emiel J T Rutgers
BACKGROUND: The MINDACT trial showed excellent 5-year distant metastasis-free survival of 94·7% (95% CI 92·5-96·2) in patients with breast cancer of high clinical and low genomic risk who did not receive chemotherapy. We present long-term follow-up results together with an exploratory analysis by age. METHODS: MINDACT was a multicentre, randomised, phase 3 trial done in 112 academic and community hospitals in nine European countries. Patients aged 18-70 years, with histologically confirmed primary invasive breast cancer (stage T1, T2, or operable T3) with up to three positive lymph nodes, no distant metastases, and a WHO performance status of 0-1 were enrolled and their genomic risk (using the MammaPrint 70-gene signature) and clinical risk (using a modified version of Adjuvant! Online) were determined...
March 12, 2021: Lancet Oncology
https://read.qxmd.com/read/33721560/adjuvant-atezolizumab-versus-observation-in-muscle-invasive-urothelial-carcinoma-imvigor010-a-multicentre-open-label-randomised-phase-3-trial
#20
Joaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, Peter Albers, Stephane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H O'Donnell, Jonathan E Rosenberg, Daniel M Geynisman, Daniel P Petrylak, Jean Hoffman-Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S van der Heijden, Cora N Sternberg, Nicole N Davarpanah, Thomas Powles
BACKGROUND: Despite standard curative-intent treatment with neoadjuvant cisplatin-based chemotherapy, followed by radical surgery in eligible patients, muscle-invasive urothelial carcinoma has a high recurrence rate and no level 1 evidence for adjuvant therapy. We aimed to evaluate atezolizumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma. METHOD: In the IMvigor010 study, a multicentre, open-label, randomised, phase 3 trial done in 192 hospitals, academic centres, and community oncology practices across 24 countries or regions, patients aged 18 years and older with histologically confirmed muscle-invasive urothelial carcinoma and an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 were enrolled within 14 weeks after radical cystectomy or nephroureterectomy with lymph node dissection...
March 12, 2021: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"